We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01027234
Recruitment Status : Terminated (Pre-Clinical Safety Tox Findings)
First Posted : December 7, 2009
Last Update Posted : May 26, 2010
Information provided by:

Study Description
Brief Summary:

The main purpose of this study is to assess the safety and tolerability of AZD8418 after single increasing oral doses.

Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how the study drug enters and leaves the body and how your body acts on the study drug) of AZD8418. Part B of the study will assess the effect of food on the safety and pharmacokinetics of AZD8418.

Condition or disease Intervention/treatment Phase
Healthy Drug: AZD8418 Drug: Placebo Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single-ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and Pharmacokinetics (Part A) and an Open-label Assessment of the Effect of Food on the Pharmacokinetics (Part B) of Orally Administered AZD8418
Study Start Date : November 2009
Primary Completion Date : March 2010
Study Completion Date : March 2010
Arms and Interventions

Arm Intervention/treatment
Experimental: 1 Drug: AZD8418
Single oral dose
Placebo Comparator: 2 Drug: Placebo
single oral dose

Outcome Measures

Primary Outcome Measures :
  1. To assess the safety and tolerability of AZD8418 following the oral administration of single ascending doses and to estimate the maximum tolerated dose in healthy volunteers. [ Time Frame: Safety assessments will be obtained daily throughout the study ]

Secondary Outcome Measures :
  1. To characterise the pharmacokinetics of AZD8418 and its metabolites in plasma and urine, and provisionally assess the dose proportionality of the pharmacokinetics following administration of single ascending doses of AZD8418. [ Time Frame: samples will be obtained pre and post dose ]
  2. To assess the effect of food on the safety and pharmacokinetic profile of AZD8418 and its metabolites. [ Time Frame: samples will be obtained pre and post dose ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male volunteers
  • Healthy female volunteers of non-childbearing potential

Exclusion Criteria:

  • History of any clinically significant medical, neurologic, or psychiatric disease (including repeated episodes of major depression) or a disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation
  • History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD8418
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01027234

United States, Kansas
Research Site
Overland Park, Kansas, United States
Sponsors and Collaborators
Principal Investigator: Philip T. Leese, M.D. Quintiles, Inc.
More Information

Responsible Party: MSD, AstraZeneca
ClinicalTrials.gov Identifier: NCT01027234     History of Changes
Other Study ID Numbers: D2590C00001
First Posted: December 7, 2009    Key Record Dates
Last Update Posted: May 26, 2010
Last Verified: May 2010

Keywords provided by AstraZeneca:
Healthy volunteers